An awards programme aimed at reducing cardiovascular disease in diabetes patients has been unveiled by Pfizer and the European Foundation for the Study of Diabetes (EFSD).
The programme will offer research grants that will go towards developing European educational programmes, risk-assessment tools, screening and clinical intervention.
Pfizer’s senior medical director Dr Lance Berman said: “Pfizer is proud to partner with the EFSD on this new research initiative.
“As part of our commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce these risks, further our understanding of optimal treatment options, and ultimately improve the lives of the people with diabetes.”
Diabetes affects some 230 million people worldwide, and 65% of deaths in that group are down to cardiovascular disease.
EFSD chairman Professor Philippe Halban said: “We are excited about this new grant programme and partnership.
“While the EFSD has several different grant programmes, this is the first research programme partnership to focus on understanding and reducing cardiovascular risk in people with diabetes.
“This will help the medical community better understand how to prevent the devastating effects that cardiovascular disease has on the lives of the people with diabetes.”
Copyright © PA Business 2007